Nuevos anticoagulantes orales / New oral anticoagulant drugs
Rev. méd. Chile
;
139(10): 1347-1355, oct. 2011. ilus, tab
Artículo
en Español
| LILACS
| ID: lil-612205
ABSTRACT
Thromboembolic disease (TED) is the leading cause of morbidity and mortality worldwide. The hallmark of oral long-term anticoagulant therapy has been the use of vitamin K antagonists, whose anticoagulant effect is exerted inhibiting vitamin K epoxide reductase. Warfarin and acenocoumarol are the most commonly used. In the last five years several new drugs for long term anticoagulation have been developed, which can inhibit single clotting factors with the purpose of improving drug therapeutic range and, ideally, minimizing bleeding risks. This review addresses the state of the art on the clinical use of inhibitors of activated factor X and thrombin.
Texto completo:
Disponible
Índice:
LILACS (Américas)
Asunto principal:
Vitamina K
/
Trombina
/
Factor Xa
/
Anticoagulantes
Límite:
Humanos
Idioma:
Español
Revista:
Rev. méd. Chile
Asunto de la revista:
Medicina
Año:
2011
Tipo del documento:
Artículo
País de afiliación:
Chile
Institución/País de afiliación:
Pontificia Universidad Católica de Chile/CL
Similares
MEDLINE
...
LILACS
LIS